Evidence Hub

Case series evaluating the efficacy and safety of platelet-rich plasma for androgenetic alopecia in pediatric patients

Catherine Tawfik, C. Tejeda, Adrienne M. Haughton

JAAD Case Reports, 2023

3 citations

Abstract

AGA: androgenetic alopecia PRP: platelet rich plasma INTRODUCTION Androgenetic alopecia (AGA) is a form of hair loss commonly referred to as male or female pattern hair loss. It is traditionally diagnosed by clinical examination with no further testing needed. Although prevalence varies based on the population, it commonly occurs between the fourth and seventh decades of life in both sexes. AGA can also be seen in children with an average onset age of 14.8 years but can be seen as young as 6 years old. Pediatric AGA is the most common cause of hair loss in adolescence. Many treatments including minoxidil, spironolactone finasteride, dutasteride, lasers, and plateletrich plasma (PRP) have been studied in adult AGA, but not pediatrics. This is a retrospective clinical review of efficacy and safety in 4 cases of pediatric AGA treated with PRP injections (Table I).

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free